Abstract: The invention belongs in the field of medicine and can be used in the treatment of chronic and asymptomatic trichomonas infections of the urogenital tract. The invention is consisted in development of new therapeutic substance of plant origin with minimal side effects for treatment of various forms of trichomonad infection. The new therapeutic substance, of plant origin, is an olive coloured paste. It is composed of a conifer green needle complex (CGNC) and has a coniferous smell and antiprotozoal activity against Trichomonas vaginalis (when tested in an in vitro model). At a concentration of 100 mg/ml CGNC has trichomonadocitic and trichomonadostatic properties. At 300 mg/ml it suppresses the growth of T. vaginalis and at 500 mg/ml it kills this organism.

Abstract: The invention belongs in the field of medicine and can be used in the treatment of chronic and asymptomatic trichomonas infections of the urogenital tract. The invention is consisted in development of new therapeutic substance of plant origin with minimal side effects for treatment of various forms of trichomonad infection. The new therapeutic substance, of plant origin, is an olive coloured paste. It is composed of a conifer green needle complex (CGNC) and has a coniferous smell and antiprotozoal activity against Trichomonas vaginalis (when tested in an in vitro model). At a concentration of 100 mg/ml CGNC has trichomonadocitic and trichomonadostatic properties. At 300 mg/ml it suppresses the growth of T. vaginalis and at 500 mg/ml it kills this organism.

Abstract: The invention belongs to the area of medicine and can be used as a therapeutic substance and as an inhibitor of the growth of Helicobacter pylori during anti-helicobacter therapy. The invention targets the development of a new therapeutic substance that does not cause adverse reactions or side effects in the liver, blood and other organs and is capable of suppressing H. Pylori growth and the progression of infection. Chlorophyll-carotene paste (CGNC) is used as an active ingredient of the pharmaceutical composition for anti-helicobacter therapy, Bioeffective A. It is an inhibitor of H. pylori. CGNC can be included as a therapeutic substance in anti-helicobacter therapy. The pharmaceutical composition for anti-helicobacter therapy contains a therapeutically effective amount of chlorophyll-carotene paste and pharmaceutically acceptable carriers and/or solvents. The pharmaceutical mixture is in the form of solution, suspension, capsule, or tablets.